Detalles de la búsqueda
1.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Lancet Oncol
; 17(5): 577-89, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27083334
2.
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Lancet Oncol
; 16(7): 830-8, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26051236
3.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Lancet Oncol
; 16(2): 141-51, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25589191
4.
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Lancet Oncol
; 14(1): 38-47, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23200175
5.
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.
J Clin Oncol
; 41(16): 2869-2876, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37235976
6.
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
J Thorac Oncol
; 11(3): 380-90, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26823294
7.
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
J Clin Oncol
; 31(27): 3342-50, 2013 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23816967
8.
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
J Clin Oncol
; 31(27): 3327-34, 2013 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23816960
9.
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Clin Cancer Res
; 18(2): 555-67, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048237
10.
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 68(6): 1619-28, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21953275
Resultados
1 -
10
de 10
1
Próxima >
>>